Date of Presentation
5-2-2019 12:00 AM
College
School of Osteopathic Medicine
Poster Abstract
Ulcerative Colitis (UC) is a chronic inflammatory disease of the bowel, with one third of patients requiring a colectomy for fulminant disease and tissue dysplasia. In 2007, infliximab was approved for induction and maintenance of remission in UC, with some evidence to suggest a potential reduction in colectomies. The aim of this study is to examine relative colectomy rates for UC among different ethnicities from 2007 to 2014 in order to evaluate for development of new trends or disparities.
Discrepancies in colectomy rates and timing are seen in our models which mirror closely findings in a prior study from 1999-2003 (Nguyen GC, et al. Racial and Geographic Variations in Colectomy Rates Among Hospitalized Ulcerative Colitis Patients. Clinical Gastroenterology and Hepatology 2006; 4: 15071513.e1). The consistency between our findings suggests that the availability of infliximab has not altered the relative differences in surgical management of inpatients of different ethnicities with UC flares. Closer study of utilization and response to UC therapy across ethnic and demographic lines is needed to better elucidate whether such practices are based on true phenotypic differences in disease or bias, as it appears white, wealthier patients continue to more readily and rapidly receive colectomies.
Keywords
ulcerative colitis, colectomy, infliximab, ethnic disparity
Disciplines
Digestive System Diseases | Gastroenterology | Health Services Administration | Health Services Research | Medicine and Health Sciences | Pharmacoeconomics and Pharmaceutical Economics
Document Type
Poster
Included in
Digestive System Diseases Commons, Gastroenterology Commons, Health Services Administration Commons, Health Services Research Commons, Pharmacoeconomics and Pharmaceutical Economics Commons
Ethnic and Demographic Differences in Colectomy Rates and Timing for Ulcerative Colitis: 2007-2014
Ulcerative Colitis (UC) is a chronic inflammatory disease of the bowel, with one third of patients requiring a colectomy for fulminant disease and tissue dysplasia. In 2007, infliximab was approved for induction and maintenance of remission in UC, with some evidence to suggest a potential reduction in colectomies. The aim of this study is to examine relative colectomy rates for UC among different ethnicities from 2007 to 2014 in order to evaluate for development of new trends or disparities.
Discrepancies in colectomy rates and timing are seen in our models which mirror closely findings in a prior study from 1999-2003 (Nguyen GC, et al. Racial and Geographic Variations in Colectomy Rates Among Hospitalized Ulcerative Colitis Patients. Clinical Gastroenterology and Hepatology 2006; 4: 15071513.e1). The consistency between our findings suggests that the availability of infliximab has not altered the relative differences in surgical management of inpatients of different ethnicities with UC flares. Closer study of utilization and response to UC therapy across ethnic and demographic lines is needed to better elucidate whether such practices are based on true phenotypic differences in disease or bias, as it appears white, wealthier patients continue to more readily and rapidly receive colectomies.